PET imaging safety study for leg artery disease patients and healthy volunteers
Part of Heart & circulation clinical trials.
This study tests whether a new radioactive tracer called APAC is safe and can be seen in PET/CT scans. It is for people with blocked leg arteries (PAOD/CLI) and for healthy volunteers. The goal is to see where the tracer goes in the body and how the body tolerates it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old (patients) or 40 to 80 years old (healthy volunteers).
- You have leg artery disease (Rutherford categories 1-4 or a certain type of category 5).
- Your kidney function is good enough (eGFR above 46 for patients).
- You are not taking blood thinners like warfarin or newer drugs, except for aspirin or clopidogrel alone.
- You have not had surgery or a procedure to open leg arteries in the last year (patients).
- You speak and understand Dutch.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This trial uses a special PET scan to see how an experimental drug, CIT-013, targets inflammation in the body. It's for people with rheumatoid arthritis to better understand how the drug works.
This trial studies plaque activity in leg arteries using a new imaging method to understand artery disease better. It may help people with peripheral artery disease get more targeted treatment.
This early-stage study tests a new PET imaging agent (a radioactive tracer used in medical imaging) to understand how it moves through the body and the radiation dose it delivers. Researchers need healthy volunteers to help establish whether this imaging tool is safe for future patient use.
This trial tests a very low dose of a radioactive tracer (18F-flurpiridaz) for PET scans of the heart. It aims to see if using less radiation still produces clear images, which may be safer for patients who need repeated scans.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
Hear when a new Peripheral Arterial Occlusive Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.